Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort
The onset of numerous diseases in human populations can often be attributed to a complex interplay of genetic predispositions, lifestyle factors, and exposure to polluted environments
Mechanism Diagram GHK-Cu vs Growth Peptides (Key Differences) GHK-Cu - Copper binding tripeptide - Acts locally in tissue - Modulates gene expression and ECM remodelling - Not endocrine - Does not elevate GH or IGF-1 GH Secretagogues (e.g., Ipamorelin, Hexarelin, MK-677) - Act via endocrine receptors - Stimulate systemic GH release - Increase IGF-1 - Primarily hormonal These compounds operate in completely different biological domains
Retatrutide as a single agent outperforms cagrilintide as a single agent by a significant margin
Pintar JE, Schuller A, Cerro JA, Czick M, Grewal A, Green B
Acknowledgements The authors would like to thank Henrik Kim Nielsen, Jens Heisterberg, and Karen Hauda (Novo Nordisk A/S, Denmark), and Gina MacNeil (Novo Nordisk Inc, United States) for review of, and input to, the manuscript, as well as Tina stergaard, Sisse Lakner Schmidt, and Michala Cronberg (Novo Nordisk A/S, Denmark) for help with physical stability analyses
